| Added by | liaudet-coopman |
|---|---|
| Group name | EquipeELC |
| Item Type | Journal Article |
| Title | Targeting homologous repair deficiency in breast and ovarian cancers: Biological pathways, preclinical and clinical data |
| Creator | Chartron et al. |
| Author | Elodie Chartron |
| Author | Charles Theillet |
| Author | Séverine Guiu |
| Author | William Jacot |
| Abstract | Mutation or epigenetic silencing of homologous recombination (HR) repair genes is characteristic of a growing proportion of triple-negative breast cancers (TNBCs) and high-grade serous ovarian carcinomas. Defects in HR lead to genome instability, allowing cells to acquire the multiple genetic alterations essential for cancer development. However, this deficiency can also be exploited by using DNA damaging agents or by targeting compensatory repair pathways. A noteworthy example is treatment of TNBC and epithelial ovarian cancer harboring BRCA1/2 germline mutations using platinum salts and/or PARP inhibitors. Dramatic responses to PARP inhibitors may support a wider use in the HR-deficient population beyond those with mutated germline BRCA1 and 2. In this review, we discuss HR deficiency hallmarks as predictive biomarkers for platinum salt and PARP inhibitor sensitivity for selecting patients affected by TNBC or epithelial ovarian cancer who could benefit from these therapeutic options. |
| Publication | Critical Reviews in Oncology/Hematology |
| Volume | 133 |
| Pages | 58-73 |
| Date | Jan 2019 |
| Journal Abbr | Crit. Rev. Oncol. Hematol. |
| Language | eng |
| DOI | 10.1016/j.critrevonc.2018.10.012 |
| ISSN | 1879-0461 |
| Short Title | Targeting homologous repair deficiency in breast and ovarian cancers |
| Library Catalog | PubMed |
| Extra | PMID: 30661659 |
| Tags | Antineoplastic Agents, BRCAness, Breast Neoplasms, Clinical Trials as Topic, Drug Evaluation, Preclinical, Epithelial ovarian cancer, Female, Homologous recombination deficiency, Humans, Molecular Targeted Therapy, Mutation, Ovarian Neoplasms, PARP inhibitor, Platinum salts, Predictive biomarker, Prognostic biomarker, Recombinational DNA Repair, review, Signal Transduction, Triple-negative breast cancer |
| Date Added | 2019/05/28 - 15:38:35 |
| Date Modified | 2019/05/29 - 12:27:30 |
| Notes and Attachments | PubMed entry (Attachment) |
Institut de Recherche en Cancérologie de
